{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:08:19Z","timestamp":1778692099411,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Intramural Grant All India Institute of Medical Sciences New Delhi","award":["E8-734\/A-734\/2019\/RS"],"award-info":[{"award-number":["E8-734\/A-734\/2019\/RS"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-024-02299-4","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T05:02:38Z","timestamp":1708405358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical significance of blocking novel immune checkpoint B7-H4 in urothelial carcinoma of bladder as a potential therapeutic target"],"prefix":"10.1007","volume":"41","author":[{"given":"David","family":"Raja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aishwarya","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santosh","family":"Kurra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brusabhanu","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Kaushal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alpana","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7633-9973","authenticated-orcid":false,"given":"Prabhjot","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"issue":"3","key":"2299_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2299_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/his.13734","volume":"74","author":"MJ Magers","year":"2019","unstructured":"Magers MJ, Lopez-Beltran A, Montironi R, Williamson SR, Kaimakliotis HZ, Cheng L. Staging of bladder cancer. Histopathology. 2019;74(1):112\u201334. https:\/\/doi.org\/10.1111\/his.13734.","journal-title":"Histopathology"},{"issue":"21","key":"2299_CR3","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602\u20138. https:\/\/doi.org\/10.1200\/JCO.2005.07.757.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2299_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, et al. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012;30(2):191\u20139. https:\/\/doi.org\/10.1200\/JCO.2011.37.3571.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2299_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2018","unstructured":"Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29(1):71\u201383. https:\/\/doi.org\/10.1093\/annonc\/mdx686.","journal-title":"Ann Oncol"},{"issue":"2","key":"2299_CR6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","volume":"18","author":"ER Plimack","year":"2017","unstructured":"Plimack ER, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18(2):212\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(17)30007-4.","journal-title":"Lancet Oncol"},{"issue":"10031","key":"2299_CR7","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial. Lancet. 2016;387(10031):1909\u201320. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4.","journal-title":"Lancet"},{"issue":"1","key":"2299_CR8","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3(1):17022. https:\/\/doi.org\/10.1038\/nrdp.2017.22.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2299_CR9","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrurol.2017.190","volume":"15","author":"A Siefker-Radtke","year":"2018","unstructured":"Siefker-Radtke A, Curti B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol. 2018;15(2):112\u201324. https:\/\/doi.org\/10.1038\/nrurol.2017.190.","journal-title":"Nat Rev Urol"},{"issue":"10122","key":"2299_CR10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(17)33297-X.","journal-title":"Lancet"},{"key":"2299_CR11","unstructured":"Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease: Trends in Immunology. https:\/\/www.cell.com\/trends\/immunology\/fulltext\/S1471-4906(13)00110-5?script=true. Accessed 07 Aug 2022"},{"issue":"9","key":"2299_CR12","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00268-011-1186-4","volume":"35","author":"T Arigami","year":"2011","unstructured":"Arigami T, Uenosono Y, Ishigami S, Hagihara T, Haraguchi N, Natsugoe S. Clinical significance of the B7\u2013H4 coregulatory molecule as a novel prognostic marker in gastric cancer. World J Surg. 2011;35(9):2051\u20137. https:\/\/doi.org\/10.1007\/s00268-011-1186-4.","journal-title":"World J Surg"},{"issue":"2","key":"2299_CR13","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1177\/147323001204000211","volume":"40","author":"S-Q Sun","year":"2012","unstructured":"Sun S-Q, Jiang C-G, Lin Y, Jin Y-L, Huang P-L. Enhanced T cell immunity by B7\u2013H4 downregulation in nonsmall-cell lung cancer cell lines. J Int Med Res. 2012;40(2):497\u2013506. https:\/\/doi.org\/10.1177\/147323001204000211.","journal-title":"J Int Med Res"},{"issue":"9","key":"2299_CR14","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/IGC.0b013e3181ad0fa2","volume":"19","author":"L Cheng","year":"2009","unstructured":"Cheng L, et al. B7-H4 expression promotes tumorigenesis in ovarian cancer. Int J Gynecol Cancer. 2009;19(9):1481\u20136. https:\/\/doi.org\/10.1111\/IGC.0b013e3181ad0fa2.","journal-title":"Int J Gynecol Cancer"},{"issue":"15","key":"2299_CR15","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2019.37.15_suppl.2529","volume":"37","author":"JC Sachdev","year":"2019","unstructured":"Sachdev JC, et al. Phase 1a\/1b study of first-in-class B7\u2013H4 antibody, FPA150, as monotherapy in patients with advanced solid tumors. JCO. 2019;37(15):2529\u20132529. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.2529.","journal-title":"JCO"},{"issue":"16","key":"2299_CR16","doi-asserted-by":"publisher","first-page":"TPS3153","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3153","volume":"40","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, et al. First-in-human study of the B7\u2013H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced\/metastatic solid tumors. JCO. 2022;40(16):TPS3153\u2013TPS3153. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS3153.","journal-title":"JCO"},{"issue":"4","key":"2299_CR17","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.immuni.2018.03.018","volume":"48","author":"J Li","year":"2018","unstructured":"Li J, et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells. Immunity. 2018;48(4):773-786.e5. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.018.","journal-title":"Immunity"},{"key":"2299_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-021-04299-8","author":"A Singh","year":"2021","unstructured":"Singh A, et al. Autophagy-associated HMGB-1 as a novel potential circulating non-invasive diagnostic marker for detection of urothelial carcinoma of bladder. Mol Cell Biochem. 2021. https:\/\/doi.org\/10.1007\/s11010-021-04299-8.","journal-title":"Mol Cell Biochem"},{"issue":"11","key":"2299_CR19","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1007\/s00432-019-03024-9","volume":"145","author":"V Anand","year":"2019","unstructured":"Anand V, et al. CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladder through Akt\/ERK\/STAT3 pathways: novel therapeutic approach. J Cancer Res Clin Oncol. 2019;145(11):2649\u201361. https:\/\/doi.org\/10.1007\/s00432-019-03024-9.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1\u20132","key":"2299_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11010-019-03648-y","volume":"464","author":"M Khandelwal","year":"2020","unstructured":"Khandelwal M, et al. RASSF1A\u2013Hippo pathway link in patients with urothelial carcinoma of bladder: plausible therapeutic target. Mol Cell Biochem. 2020;464(1\u20132):51\u201363. https:\/\/doi.org\/10.1007\/s11010-019-03648-y.","journal-title":"Mol Cell Biochem"},{"issue":"10","key":"2299_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.humimm.2013.06.032","volume":"74","author":"S Chugh","year":"2013","unstructured":"Chugh S, Anand V, Swaroop L, Sharma M, Seth A, Sharma A. Involvement of Th17 cells in patients of urothelial carcinoma of bladder. Hum Immunol. 2013;74(10):1258\u201362. https:\/\/doi.org\/10.1016\/j.humimm.2013.06.032.","journal-title":"Hum Immunol"},{"issue":"1","key":"2299_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.urolonc.2009.06.002","volume":"29","author":"A Satyam","year":"2011","unstructured":"Satyam A, Singh P, Badjatia N, Seth A, Sharma A. A disproportion of TH1\/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol. 2011;29(1):58\u201365. https:\/\/doi.org\/10.1016\/j.urolonc.2009.06.002.","journal-title":"Urol Oncol"},{"issue":"7","key":"2299_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1186\/2047-783X-16-7-295","volume":"16","author":"Y Qian","year":"2011","unstructured":"Qian Y, et al. Development of a novel monoclonal antibody to B7\u2013H4: characterization and biological activity. Eur J Med Res. 2011;16(7):295\u2013302. https:\/\/doi.org\/10.1186\/2047-783X-16-7-295.","journal-title":"Eur J Med Res"},{"issue":"45","key":"2299_CR24","doi-asserted-by":"publisher","first-page":"73068","DOI":"10.18632\/oncotarget.12230","volume":"7","author":"T Zhang","year":"2016","unstructured":"Zhang T, et al. The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis. Oncotarget. 2016;7(45):73068\u201379. https:\/\/doi.org\/10.18632\/oncotarget.12230.","journal-title":"Oncotarget"},{"issue":"39","key":"2299_CR25","doi-asserted-by":"publisher","first-page":"15016","DOI":"10.1073\/pnas.0801497105","volume":"105","author":"SD Blackburn","year":"2008","unstructured":"Blackburn SD, Shin H, Freeman GJ, Wherry EJ. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc Natl Acad Sci USA. 2008;105(39):15016\u201321. https:\/\/doi.org\/10.1073\/pnas.0801497105.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2299_CR26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.13887","volume":"110","author":"B Wang","year":"2019","unstructured":"Wang B, et al. Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci. 2019;110(2):489\u201398. https:\/\/doi.org\/10.1111\/cas.13887.","journal-title":"Cancer Sci"},{"key":"2299_CR27","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.2147\/CMAR.S176937","volume":"11","author":"X Ding","year":"2019","unstructured":"Ding X, et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Cancer Manag Res. 2019;11:4171\u201384. https:\/\/doi.org\/10.2147\/CMAR.S176937.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"2299_CR28","first-page":"1","volume":"54","author":"T Matsunaga","year":"2011","unstructured":"Matsunaga T, Saito H, Ikeguchi M. Increased B7\u2013H1 and B7\u2013H4 expressions on circulating monocytes and tumor-associated macrophages are involved in immune evasion in patients with gastric cancer. Yonago Acta Med. 2011;54(1):1\u201310.","journal-title":"Yonago Acta Med"},{"issue":"1","key":"2299_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2014.03.553","volume":"134","author":"JB Smith","year":"2014","unstructured":"Smith JB, Stashwick C, Powell DJ. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look. Gynecol Oncol. 2014;134(1):181\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2014.03.553.","journal-title":"Gynecol Oncol"},{"issue":"60","key":"2299_CR30","doi-asserted-by":"publisher","first-page":"101994","DOI":"10.18632\/oncotarget.22025","volume":"8","author":"O Arrieta","year":"2017","unstructured":"Arrieta O, et al. Expression of PD-1\/PD-L1 and PD-L2 in peripheral T-cells from non-small cell lung cancer patients. Oncotarget. 2017;8(60):101994\u20132005. https:\/\/doi.org\/10.18632\/oncotarget.22025.","journal-title":"Oncotarget"},{"issue":"10","key":"2299_CR31","first-page":"6768","volume":"7","author":"M Fan","year":"2014","unstructured":"Fan M, et al. B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma. Int J Clin Exp Pathol. 2014;7(10):6768\u201375.","journal-title":"Int J Clin Exp Pathol"},{"key":"2299_CR32","doi-asserted-by":"publisher","first-page":"107144","DOI":"10.1016\/j.intimp.2020.107144","volume":"90","author":"S Ding","year":"2021","unstructured":"Ding S, et al. Overexpression of B7\u2013H4 is associated with infiltrating immune cells and poor prognosis in metastatic colorectal cancer. Int Immunopharmacol. 2021;90:107144. https:\/\/doi.org\/10.1016\/j.intimp.2020.107144.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"2299_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2005.08.060","volume":"100","author":"B Tringler","year":"2006","unstructured":"Tringler B, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol. 2006;100(1):44\u201352. https:\/\/doi.org\/10.1016\/j.ygyno.2005.08.060.","journal-title":"Gynecol Oncol"},{"issue":"49","key":"2299_CR34","doi-asserted-by":"publisher","first-page":"19458","DOI":"10.1073\/pnas.0709802104","volume":"104","author":"X Zang","year":"2007","unstructured":"Zang X, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci USA. 2007;104(49):19458\u201363. https:\/\/doi.org\/10.1073\/pnas.0709802104.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2299_CR35","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.3892\/ol.2014.2522","volume":"8","author":"W-H Liu","year":"2014","unstructured":"Liu W-H, et al. B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms. Oncol Lett. 2014;8(6):2527\u201334. https:\/\/doi.org\/10.3892\/ol.2014.2522.","journal-title":"Oncol Lett"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-024-02299-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-024-02299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:02:32Z","timestamp":1709078552000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-024-02299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2299"],"URL":"https:\/\/doi.org\/10.1007\/s12032-024-02299-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3321992\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"3 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research involving human patients and healthy individuals had provided written informed consent. This study has been approved by Institutional Human Ethics Committee of All India Institute of Medical Sciences, New Delhi, India (IEC-685\/06.09.2019) prior to its commencement.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal rights"}}],"article-number":"74"}}